254 related articles for article (PubMed ID: 26439378)
1. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Meng X; Li Y; Tang H; Mao W; Yang H; Wang X; Ding X; Xie S
Amino Acids; 2016 Feb; 48(2):487-97. PubMed ID: 26439378
[TBL] [Abstract][Full Text] [Related]
2. Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer.
Lu J; Zhou K; Yin X; Xu H; Ma B
Comput Biol Chem; 2019 Feb; 78():290-296. PubMed ID: 30605854
[TBL] [Abstract][Full Text] [Related]
3. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
[TBL] [Abstract][Full Text] [Related]
4. Integrated Exploitation of the Structural Diversity Space of Chemotherapy Drugs to Selectively Inhibit HER2 T798M Mutant in Lung Cancer.
Wang YW; Zhang HY; Li JS; Wang XW
Chem Biodivers; 2017 Mar; 14(3):. PubMed ID: 27696725
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.
Zheng YB; Yu Y; Chen B; Hu JL; Jing T; Zhang XP
Cancer Invest; 2016; 34(3):123-9. PubMed ID: 26934461
[TBL] [Abstract][Full Text] [Related]
6. Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.
Yu X; Wang T; Lou Y; Li Y
Mol Inform; 2016 Jan; 35(1):25-35. PubMed ID: 27491651
[TBL] [Abstract][Full Text] [Related]
7. Systematic profiling of staralog response to acquired drug resistant kinase gatekeeper mutations in targeted cancer therapy.
Yang Y; Qiu Y; Liu X; Liu Y; Yin Y; Li P
Amino Acids; 2020 Apr; 52(4):511-521. PubMed ID: 32206932
[TBL] [Abstract][Full Text] [Related]
8. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
[TBL] [Abstract][Full Text] [Related]
9. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
[TBL] [Abstract][Full Text] [Related]
10. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
11. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Wang SE; Narasanna A; Perez-Torres M; Xiang B; Wu FY; Yang S; Carpenter G; Gazdar AF; Muthuswamy SK; Arteaga CL
Cancer Cell; 2006 Jul; 10(1):25-38. PubMed ID: 16843263
[TBL] [Abstract][Full Text] [Related]
12. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
[TBL] [Abstract][Full Text] [Related]
13. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
Yang B; Zhang H; Wang H
J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
[TBL] [Abstract][Full Text] [Related]
14. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
Ishikawa T; Seto M; Banno H; Kawakita Y; Oorui M; Taniguchi T; Ohta Y; Tamura T; Nakayama A; Miki H; Kamiguchi H; Tanaka T; Habuka N; Sogabe S; Yano J; Aertgeerts K; Kamiyama K
J Med Chem; 2011 Dec; 54(23):8030-50. PubMed ID: 22003817
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
17. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
[TBL] [Abstract][Full Text] [Related]
18. An Acquired
Hanker AB; Brewer MR; Sheehan JH; Koch JP; Sliwoski GR; Nagy R; Lanman R; Berger MF; Hyman DM; Solit DB; He J; Miller V; Cutler RE; Lalani AS; Cross D; Lovly CM; Meiler J; Arteaga CL
Cancer Discov; 2017 Jun; 7(6):575-585. PubMed ID: 28274957
[TBL] [Abstract][Full Text] [Related]
19. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
20. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]